{"id":"W2731312174","doi":"10.1200/jco.2017.35.15_suppl.106","title":"A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Clinical endpoint; Adverse effect; Oncology; Nausea; Cancer; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001694118,0.0005793378,0.0009993288,0.0002990619,0.0001869836,0.0006522555,0.000568561,0.0004323417,0.00165706],"category_scores_gemma":[0.0008778455,0.0002704451,0.0007654502,0.0005187441,0.000211445,0.0004173506,0.0002405458,0.0008995236,0.000356641],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005727734,"about_ca_system_score_gemma":0.0006298856,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009802026,"about_ca_topic_score_gemma":0.002535274,"domain_scores_codex":[0.9996939,0.000135982,0.00001732317,0.00006387035,0.00005125069,0.00003777973],"domain_scores_gemma":[0.9995208,0.00009290312,0.0001346889,0.00004930213,0.00004854023,0.0001539052],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2003836,0.01194623,0.2651096,0.001959513,0.00506747,0.0006916868,0.0003574247,0.006134048,0.08775463,0.0003503913,0.01490386,0.4053416],"study_design_scores_gemma":[0.143777,0.2364607,0.5530739,0.0002156394,0.005281694,0.004297994,0.0002159204,0.007382519,0.01382121,0.0004256631,0.03494831,0.00009936329],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9848344,0.007729242,0.0007882863,0.0002826996,0.00004071005,0.0008557542,0.00299341,0.00009202208,0.002383384],"genre_scores_gemma":[0.9830965,0.003796603,0.001732429,0.0005218256,0.0000594621,0.0004394162,0.008861096,0.00003105279,0.001461605],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001694118,"threshold_uncertainty_score":0.008959413,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1233600787859633,"score_gpt":0.5077908715803896,"score_spread":0.3844307927944263,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}